Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited announced the extension of the effective date for the ‘Genetic Testing in Oncology: Specific Tests’ Local Coverage Determination (LCD) by Medicare to 24 April 2025. This extension follows the company’s efforts to engage with various stakeholders, including Medicare and political leaders, to revise or withdraw the LCD, which has implications for the company’s operations and market positioning in the cancer diagnostics industry.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder tests worldwide, supported by its certified laboratories in New Zealand and the USA. The Cxbladder test is a urine-based genomic biomarker test used for detecting and monitoring bladder cancer, and is backed by extensive clinical research and publications. The test is widely used in the US and accessible in New Zealand through public healthcare and online purchase options.
YTD Price Performance: -54.93%
Average Trading Volume: 12,160
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $26.75M
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.
